Aspirin in Patients Receiving Oral Anticoagulation
Abstract
To the Editor: In the AQUATIC trial reported by Lemesle et al. (Oct. 23 issue), 1 patients were at markedly increased risk for atrial fibrillation, as evidenced by a median CHA 2 DS 2 -VASc score of 4.0 and a history of atrial fibrillation in 89%. Accordingly, the predominant rationale for prescribing aspirin in this high-risk cohort was the prevention of cerebrovascular events, as the authors themselves acknowledged: “an indication … often for stroke prevention when atrial fibrillation is present.” In the aspirin group, 6 patients had a stroke, as compared with 11 patients in the placebo group. Yet, the authors — prioritizing the composite . . .
Fields of Study & Subjects
Atrial Fibrillation Management and Outcomes
Antiplatelet Therapy and Cardiovascular Diseases
Acute Ischemic Stroke Management
Publication details
- Journal / source
- New England Journal of Medicine
- Volume
- 394
- Issue
- 5
- Pages
- 515–518
- Publication date
- 28 January 2026
- Language
- EN